Interleukin-1 as a therapeutic target in gout.

Details

Serval ID
serval:BIB_CCD5AB8E4EB6
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Interleukin-1 as a therapeutic target in gout.
Journal
Current Opinion in Rheumatology
Author(s)
Dumusc A., So A.
ISSN
1531-6963 (Electronic)
ISSN-L
1040-8711
Publication state
Published
Issued date
2015
Peer-reviewed
Oui
Volume
27
Number
2
Pages
156-163
Language
english
Notes
Publication types: Journal Article Publication Status: ppublish
Abstract
PURPOSE OF REVIEW: To give an overview of current evidence for interleukin (IL)-1 blockade in the management of gout.
RECENT FINDINGS: Three IL-1 blockers are currently available for clinical use: anakinra, rilonacept and canakinumab. Recent studies have focused on drugs with a long half-life: rilonacept and canakinumab. For treatment of acute gouty arthritis, three randomized controlled trials (RCTs) showed efficacy of canakinumab with some safety concerns and one RCT failed to show efficacy of rilonacept. For prevention of gout flare when starting uric acid lowering therapy (ULT), four RCTs showed efficacy of rilonacept and one RCT showed efficacy of canakinumab.
SUMMARY: There is sufficient evidence supporting the use of IL-1 blockers for treatment of acute gouty arthritis or for prevention of gout flares when starting ULT in selected patients, with contraindications or intolerance to conventional therapy. More data are needed to assess safety and to specify their use in routine practice.
Pubmed
Web of science
Create date
06/03/2015 19:06
Last modification date
20/08/2019 15:47
Usage data